Skip to main content
OpenTrials
Completed

NCT Number: NCT02164201

Post Market Surveillance Study Evaluating BioFoam Surgical Matrix in Cardiovascular Surgery

This is a prospective, multicenter, single-arm study designed to collect clinical data to support the safety and effectiveness of BioFoam used as a surgical adjunct to anastomotic hemostasis following cardiovascular surgery.

The overall objective of this clinical study is to collect clinical data supporting the safety and effectiveness of BioFoam used as a surgical adjunct to anastomotic hemostasis following cardiovascular surgery. This study is intended as a post-market surveillance (follow-up) study.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

German Heart Center, Munich, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is undergoing an elective cardiac or cardiovascular procedure;
  • Subject is willing and able to give prior written informed consent for investigation participation; and
  • Subject is > 18 years of age.

Intraoperative inclusion criteria include:

  • Subject that requires the use of an adjunctive surgical hemostatic agent to the repair site to control generalized oozing following standard repair procedures (such as sutures and staples).

Exclusion criteria

  • • Subject with known hypersensitivity to albumin, bovine products, or glutaraldehyde;
  • Subject with active infection (either systemic or in the repair region);
  • Subject whose pathology or underlying disease state makes them an unacceptable candidate for a clinical investigation in the opinion of the Investigator;
  • Subject diagnosed with a coagulation disorder;
  • Subject with abnormal calcium metabolism (e.g., chronic renal failure, hyperparathyroidism);
  • Subject whose life expectancy is less than that required for the prescribed follow-up duration;
  • Subject who is pregnant, planning on becoming pregnant during the follow-up period, or actively breast-feeding; or
  • Subject who is immunocompromised.

Intraoperative exclusion criteria include:

  • Any major intraoperative bleeding incidences (i.e., American College of Surgeons Advanced Trauma Life Support Class II, III, or IV Hemorrhage).

Treatment and study plan

Primary outcomes

  1. Achievement of haemostasis

    Time frame: 3 minutes after application

Secondary outcomes

  1. Time to haemostasis

    Time frame: measured through to 10 minutes

Sponsors and collaborators

Lead sponsor

CryoLife Europa

Industry

Registry information

Official study title

Post Market Surveillance Study Evaluating the Operative Management of Anastomotic Bleeding by Means of an Adjunctive Application of BioFoam Surgical Matrix in Cardiovascular Surgery

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Jun 16, 2014
Registry last updated
Jul 29, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.